Does Kentucky Medicaid Cover Wegovy or Zepbound? Strict Routes, No Weight Loss

No. Kentucky Medicaid excludes drugs used for weight loss under state regulation, so Wegovy and Zepbound are not covered for that purpose.^[1] As of November 2026, prior authorization can approve Wegovy for heart-risk reduction from age 45 or for the liver disease MASH, and Zepbound for sleep apnea, but none of the three routes accepts someone with type 2 diabetes.^[2][3]

Does Kentucky Medicaid cover Wegovy for weight loss?

No. The regulation that governs Kentucky’s outpatient drug benefit lists drugs taken to lose or gain weight, or for anorexia, among the categories it will not pay for.^[1] Federal law gives every state that option.^[7] The Kentucky rule carries one qualification: the exclusion applies unless the state lists the drug or use as covered on an outpatient drug list.^[1] Neither drug’s current criteria include a weight-loss use, and Wegovy and Zepbound do not appear on the November 2026 drug list, so the door stays shut for now.^[2][3][14] Our explainer on why Medicaid treats Ozempic and Wegovy differently covers the federal background.

Your managed care plan does not change this. One prior authorization form serves both managed care and fee-for-service members, with separate phone lines, (844) 336-2676 for plan members and (877) 403-6034 for fee-for-service, and a shared fax, (858) 357-2612.^[4]

When will Kentucky Medicaid pay for Wegovy or Zepbound?

Every approval lasts six months, for first requests and renewals alike.^[2][3] The diabetes exclusions push people with type 2 diabetes toward the diabetes drugs. On the November 2026 drug list, Mounjaro, the Ozempic pen, Trulicity and Victoza are preferred but still need prior authorization, and Rybelsus, the Ozempic tablet, exenatide and liraglutide are non-preferred.^[14] Those approvals ask for a type 2 diabetes diagnosis backed by an A1c of 6.5% or higher, also run six months, and still bar weight-loss use.^[15]

What does Kentucky require for Wegovy and heart disease?

The rules follow SELECT, the trial behind this use, which enrolled people 45 and older with a past heart attack, stroke or symptomatic artery disease, a BMI of at least 27 and no diabetes.^[10] Kentucky asks for each of those, plus a progress note from the past year documenting the heart event.^[2] It goes further on treatment: claims history must show the member on a cholesterol drug, such as a moderate to high intensity statin, and at least one of a beta-blocker, a RAS inhibitor such as an ACE inhibitor or ARB, or an antiplatelet drug like aspirin.^[2] A prescriber can explain instead why those drugs cannot be used.^[2]

The exclusion list is long. Besides diabetes, it bars class IV heart failure, end-stage kidney disease or dialysis, a planned procedure to open a heart, neck or leg artery, and a woman who is pregnant, breastfeeding, planning a pregnancy, or able to become pregnant without highly effective contraception.^[2] The label is broader: it takes in any adult with existing heart disease who carries excess weight, at the overweight or obese level.^[8] Renewal asks for 5% weight loss from baseline, or a note assessing diet and lifestyle when that goal has not been met.^[2]

Does Kentucky Medicaid cover Zepbound for sleep apnea?

Yes, but only after a breathing device. The adult must have moderate to severe obstructive sleep apnea, a BMI of at least 30, and at least three months of a failed trial of CPAP, BiPAP or auto-adjusting PAP, or a reason the device cannot be used.^[3] A neurologist, sleep specialist or other sleep apnea specialist must prescribe it or be consulted.^[3] The label covers sleep apnea in adults with obesity and sets no device step.^[9]

Kentucky is flexible on the sleep score. It accepts an index of 15 or more events an hour that are mainly obstructive, or a score as low as 5 with at least one typical symptom such as daytime sleepiness, loud snoring or witnessed pauses in breathing.^[3] Renewal needs the score to fall by at least 15 events an hour or by half, plus 5% weight loss or a lifestyle review.^[3] The trials behind this use, SURMOUNT-OSA, tested tirzepatide both in people not using PAP and in people already on it, and found large drops in the apnea score in each group.^[11] Our guide to Zepbound for sleep apnea covers the results.

Will Kentucky Medicaid cover Wegovy for fatty liver disease?

Yes, for adults with MASH and F2 to F3 fibrosis, using the injection only.^[2] The stage can be confirmed by a liver biopsy from the past three years, a FIB-4 score above 2.67 from the past six months, or a FIB-4 between 1.3 and 2.67 followed by elastography or an ELF blood test.^[2] That list lets a blood-based score do most of the work, which can spare a biopsy. A gastroenterologist or hepatologist must be involved, and the request is refused with type 2 diabetes, cirrhosis, liver cancer or heavy drinking.^[2]

Renewal needs evidence of benefit, such as less inflammation or fat on a biopsy, or a lower fibrosis stage.^[2] The FDA approved this use on an accelerated basis.^[8] Our review of GLP-1s for MASH covers the evidence.

How do you appeal a Kentucky Medicaid denial?

Read the reason first. A missing statin claim, sleep study or FIB-4 result is a records problem; a request for weight loss alone has no route.^[1] Managed care members have 60 days from the plan’s notice to appeal to the plan, which must decide within 30 days, and then 120 days from the plan’s final letter to ask for a state hearing.^[5] Fee-for-service members must postmark a written hearing request within 30 days of the department’s notice.^[6]

Changing plans will not help, because the same criteria apply to every member.^[4] For comparison, Indiana Medicaid uses a near-identical heart route but no CPAP step, and our walkthrough of prior authorization and appeals covers what to send. The Kentucky state page collects the other Medicaid facts.

What can you do if Kentucky Medicaid will not pay?

Self-pay is the usual fallback, and Lilly’s savings card terms exclude Medicaid enrollees.^[12] In the prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, and Lilly charges $299 at the starting Zepbound KwikPen dose, $399 at 5 mg and $449 at higher doses kept on schedule.^[12][13] Read each offer’s terms on government coverage before you buy. Our roundup of the least expensive ways to pay cash for a GLP-1 compares them.